Compare Radiotherapy Plus Nimotuzumab Versus Radiotherapy Alone in Platinum-ineligible Patients With Locoregionally Advanced Head and Neck Squamous Cell Carcinoma

NCT07333274 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

335

Enrollment

OTHER

Sponsor class

Conditions

Head & Neck Squamous Cell Carcinoma
Head & Neck Cancer

Interventions

DRUG: Nimotuzumab
RADIATION: intensity-modulated technique（IMRT）

Sponsor

Shandong Cancer Hospital and Institute